News

FDA approval of SBECD-enabled Brexanolone

News 27 March, 2019
Sage Therapeutics, a biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD).
 
Captisol is used for improving solubility, stability and bioavailability of the drug.

Read more on Cyclodexrin News blog
 

BACK TO NEWS